High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

被引:16
作者
Hu, Bei [1 ]
Thall, Peter [2 ]
Milton, Denai R. [2 ]
Sasaki, Koji [3 ]
Bashir, Qaiser [4 ]
Shah, Nina [4 ]
Patel, Krina [6 ]
Popat, Uday [4 ]
Hosing, Chitra [4 ]
Nieto, Yago [4 ]
Lin, Pei [5 ]
Delgado, Ruby [4 ]
Jorgensen, Jeffrey [5 ]
Manasanch, Elisabet [6 ]
Weber, Donna [6 ]
Thomas, Sheeba [6 ]
Orlowski, Robert Z. [6 ]
Champlin, Richard [4 ]
Qazilbash, Muzaffar H. [4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd Unit 428, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Hematopathol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Lymphoma & Myeloma, Houston, TX 77030 USA
关键词
Multiple myeloma; autologous stem cell transplant; minimal residual disease; flow cytometry; high-risk cytogenetics; nearest neighbor matching; STEM-CELL TRANSPLANTATION; DIAGNOSED MULTIPLE-MYELOMA; MULTIPARAMETER FLOW-CYTOMETRY; BORTEZOMIB PLUS DEXAMETHASONE; DEEP-SEQUENCING METHOD; IN-SITU HYBRIDIZATION; MAINTENANCE THERAPY; COMPLETE RESPONSE; INTERGROUPE FRANCOPHONE; THALIDOMIDE IMPROVES;
D O I
10.1080/10428194.2018.1485908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of our study was to determine the impact of high-risk disease (HRD) and MRD on outcomes in myeloma patients receiving bortezomib-based induction followed by autologous hematopoietic stem cell transplant (auto-HSCT). HRD included t(4:14), t(14;16), del 17p, del 1p and/or amplification 1q by cytogenetics/FISH; all others were standard-risk disease (SRD). A subset of 165 newly diagnosed myeloma patients in a 2:1 ratio of HRD:SRD was generated using propensity score based nearest neighbor matching. Multiparametric flow cytometry (MFC) was used to detect MRD after auto-HSCT in select patients. MRD+ status at 3 months post auto-HSCT (hazard ratio (HR = 4.23, p = .028) and HRD (HR = 1.72, p = .026) were associated with a shorter PFS. Similarly, MRD+ 3 months post auto-HSCT (HR = 6.93, p = .08) and HRD (HR = 3.54, p < .001) and were associated with a shorter OS. Despite bortezomib-based induction, upfront auto-HSCT, and use of maintenance therapy, PFS and OS remained worse in MRD+ and HRD patients.
引用
收藏
页码:442 / 452
页数:11
相关论文
共 66 条
[1]  
[Anonymous], 2016, BLOOD
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]   Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].
Attal, Michel ;
Harousseau, Jean-Luc ;
Leyvraz, Serge ;
Doyen, Chantal ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Agha, Ibrahim Yakoub ;
Bourhis, Jean-Henri ;
Garderet, Laurent ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Renaud, Marc ;
Voillat, Laurent ;
Berthou, Christian ;
Marit, Gerald ;
Monconduit, Mathieu ;
Caillot, Denis ;
Grobois, Bernard ;
Avet-Loiseau, Herve ;
Moreau, Philippe ;
Facon, Thierry .
BLOOD, 2006, 108 (10) :3289-3294
[4]   Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].
Attal, Michel ;
Lauwers-Cances, Valerie ;
Hulin, Cyrille ;
Leleu, Xavier ;
Caillot, Denis ;
Escoffre, Martine ;
Arnulf, Bertrand ;
Macro, Margaret ;
Belhadj, Karim ;
Garderet, Laurent ;
Roussel, Murielle ;
Payen, Catherine ;
Mathiot, Claire ;
Fermand, Jean P. ;
Meuleman, Nathalie ;
Rollet, Sandrine ;
Maglio, Michelle E. ;
Zeytoonjian, Andrea A. ;
Weller, Edie A. ;
Munshi, Nikhil ;
Anderson, Kenneth C. ;
Richardson, Paul G. ;
Facon, Thierry ;
Avet-Loiseau, Herve ;
Harousseau, Jean-Luc ;
Moreau, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320
[5]   Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].
Attal, Michel ;
Lauwers-Cances, Valerie ;
Marit, Gerald ;
Caillot, Denis ;
Moreau, Philippe ;
Facon, Thierry ;
Stoppa, Anne Marie ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Garderet, Laurent ;
Decaux, Olivier ;
Leyvraz, Serge ;
Vekemans, Marie-Christiane ;
Voillat, Laurent ;
Michallet, Mauricette ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Roussel, Murielle ;
Leleu, Xavier ;
Mathiot, Claire ;
Payen, Catherine ;
Avet-Loiseau, Herve ;
Harousseau, Jean-Luc .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791
[6]   Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Moreau, Philippe ;
Charbonnel, Catherine ;
Garban, Frederic ;
Hulin, Cyrille ;
Leyvraz, Serge ;
Michallet, Mauricette ;
Yakoub-Agha, Ibrahim ;
Garderet, Laurent ;
Marit, Gerald ;
Michaux, Lucienne ;
Voillat, Laurent ;
Renaud, Marc ;
Grosbois, Bernard ;
Guillerm, Gaelle ;
Benboubker, Lotfi ;
Monconduit, Mathieu ;
Thieblemont, Catherine ;
Casassus, Philippe ;
Caillot, Denis ;
Stoppa, Anne-Marie ;
Sotto, Jean-Jacques ;
Wetterwald, Marc ;
Dumontet, Charles ;
Fuzibet, Jean-Gabriel ;
Azais, Isabelle ;
Dorvaux, Veronique ;
Zandecki, Marc ;
Bataille, Regis ;
Minvielle, Stephane ;
Harousseau, Jean-Luc ;
Facon, Thierry ;
Mathiot, Claire .
BLOOD, 2007, 109 (08) :3489-3495
[7]  
Avet-Loiseau H, 2017, BLOOD, V130
[8]   Ultra High-Risk Myeloma [J].
Avet-Loiseau, Herve .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :489-493
[9]   Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [J].
Avet-Loiseau, Herve ;
Leleu, Xavier ;
Roussel, Murielle ;
Moreau, Philippe ;
Guerin-Charbonnel, Catherine ;
Caillot, Denis ;
Marit, Gerald ;
Benboubker, Lotfi ;
Voillat, Laurent ;
Mathiot, Claire ;
Kolb, Brigitte ;
Macro, Margaret ;
Campion, Loic ;
Wetterwald, Marc ;
Stoppa, Anne-Marie ;
Hulin, Cyrille ;
Facon, Thierry ;
Attal, Michel ;
Minvielle, Stephane ;
Harousseau, Jean-Luc .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4630-4634
[10]   Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].
Barlogie, B ;
Tricot, G ;
Anaissie, E ;
Shaughnessy, J ;
Rasmussen, E ;
van Rhee, F ;
Fassas, A ;
Zangari, M ;
Hollmig, K ;
Pineda-Roman, M ;
Lee, C ;
Talamo, G ;
Thertulien, R ;
Kiwan, E ;
Krishna, S ;
Fox, M ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030